| Date | Title | Description |
| 17.10.2024 | invIOs Secures €8.2 Million to Propel Cancer Therapies Forward | In the world of biotechnology, funding is the lifeblood that keeps innovation alive. On October 15, 2024, invIOs GmbH, a Vienna-based biotech firm, announced a significant boost to its ambitions in cancer treatment. The company raised €8.2 ... |
| 15.10.2024 | invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology | Funding secures ongoing pipeline progress and achievement of preclinical and clinical milestones
Oral small molecule INV501: collaboration with Dana-Farber Cancer Institute (DFCI) making good progress; target validation and details of mecha... |
| 15.10.2024 | invIOs Raises €8.2M in Series A Funding | invIOs GmbH, a Vienna, Austria-based biotechnology company developing novel therapies for cancer, raised €8.2m in Series A funding.
Backers included existing shareholders and Ligand Pharmaceuticals, which recently acquired APEIRON, the form... |
| - | invIOs | “invIOs – innovative Immune Oncology” |
